Drugging K-RasG12C through covalent inhibitors: Mission possible?

Cancer statistics, 2009

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709 · see citing works

<i>ras</i> GENES

Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

Small GTP-Binding Proteins

Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,481 · see citing works

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · see citing works

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works

Mammalian Ras interacts directly with the serine/threonine kinase Raf.

Vojtek, A., Hollenberg, S., & Cooper, J. A. (1993) · Cell · doi:10.1016/0092-8674(93)90307-c · Cited by 1,971 · see citing works

RAS oncogenes: the first 30 years

Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · see citing works

The Guanine Nucleotide-Binding Switch in Three Dimensions

Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875 · see citing works

The resurgence of covalent drugs

Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · see citing works

Ras oncogenes: split personalities

Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras

Rodriguez‐Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A. J., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,063 · see citing works

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works

Complexes of Ras⋅GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase

Moodie, S. A., Willumsen, B. M., Weber, M. J., & Wolfman, A. (1993) · Science · doi:10.1126/science.8503013 · Cited by 968 · see citing works

ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK

Wood, K. W., Sarnecki, C., Roberts, T. M., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90076-o · Cited by 903 · see citing works

Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation

PAI, E. F., Kabsch, W., Krengel, U., Holmes, K. C., John, J., & Wittinghofer, A. (1989) · Nature · doi:10.1038/341209a0 · Cited by 879 · see citing works

The promise and peril of chemical probes

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839 · see citing works

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 828 · see citing works

Human RAS Superfamily Proteins and Related GTPases

Colicelli, J. (2004) · Science s STKE · doi:10.1126/stke.2502004re13 · Cited by 828 · see citing works

The structural basis of the activation of Ras by Sos

Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., & Kuriyan, J. (1998) · Nature · doi:10.1038/28548 · Cited by 799 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

Ras history: The saga continues

Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706 · see citing works

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

KRAS: feeding pancreatic cancer proliferation

Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675 · see citing works

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · see citing works

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618 · see citing works

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · see citing works

Targeted Covalent Inhibitors for Drug Design

Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578 · see citing works

Controlling Cell Chemistry with Caged Compounds

Adams, S., & Tsien, R. Y. (1993) · Annual Review of Physiology · doi:10.1146/annurev.ph.55.030193.003543 · Cited by 556 · see citing works

Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies

Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534 · see citing works

Oncogenic KRAS signalling in pancreatic cancer

Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504 · see citing works

Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation

Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · see citing works

Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS

Margarit, S. M., Sondermann, H., Hall, B. E., Nagar, B., Hoelz, A., Pirruccello, M., Bar‐Sagi, D., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00149-1 · Cited by 486 · see citing works

Site-directed ligand discovery

Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466 · see citing works

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

Christensen, C. L., Kwiatkowski, N. P., Abraham, B. J., Carretero, J., Al‐Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 440 · see citing works

Prolonged and tunable residence time using reversible covalent kinase inhibitors

Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A. R., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 428 · see citing works

Drugging RAS: know the enemy

Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399 · see citing works

The Ras protein superfamily: Evolutionary tree and role of conserved amino acids

Rojas, A. M., Fuentes, G., Rausell, A., & Valencia, A. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201103008 · Cited by 378 · see citing works

Ras Conformational Ensembles, Allostery, and Signaling

Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355 · see citing works

Discovery of Potent and Selective Covalent Inhibitors of JNK

Zhang, T., Iñesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 348 · see citing works

Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses.

Chang, E. H., Gonda, M. A., Ellis, R. W., Scolnick, E. M., & Lowy, D. R. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.16.4848 · Cited by 324 · see citing works

KRAS as a Therapeutic Target

McCormick, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2662 · Cited by 320 · see citing works

Covalent inhibitors design and discovery.

De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315 · see citing works

The structure of Ras protein: a model for a universal molecular switch

Wittinghofer, A., & Pal, E. F. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90156-p · Cited by 308 · see citing works

A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles

Wang, C., Weerapana, E., Blewett, M. M., & Cravatt, B. F. (2013) · Nature Methods · doi:10.1038/nmeth.2759 · Cited by 303 · see citing works

Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor

Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300 · see citing works

<i>In silico</i> discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction

Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293 · see citing works

Identification of a cellularly active SIRT6 allosteric activator

Huang, Z., Zhao, J., Deng, W., Chen, Y., Shang, J., Song, K., Zhang, L., Wang, C., Lu, S., Yang, X., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0150-0 · Cited by 277 · see citing works

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242 · see citing works

Conformational Transitions in p21 ras and in Its Complexes with the Effector Protein Raf-RBD and the GTPase Activating Protein GAP

Geyer, M., Schweins, T., Herrmann, C., Prisner, T. F., Wittinghofer, A., & Kalbitzer, H. R. (1996) · Biochemistry · doi:10.1021/bi952858k · Cited by 227 · see citing works

The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B

Lu, S., Jang, H., Nussinov, R., & Zhang, J. (2016) · Scientific Reports · doi:10.1038/srep21949 · Cited by 219 · see citing works

Drug discovery considerations in the development of covalent inhibitors

Mah, R., Thomas, J. R., & Shafer, C. M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.003 · Cited by 197 · see citing works

Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view

Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188 · see citing works

KRAS-related proteins in pancreatic cancer

Mann, K. M., Ying, H., Juan, J. M., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 186 · see citing works

The biochemistry of ras p21

Grand, R. J. A., & Owen, D. (1991) · Biochemical Journal · doi:10.1042/bj2790609 · Cited by 180 · see citing works

Allosteric Modulator Discovery: From Serendipity to Structure-Based Design

Lu, S., He, X., Ni, D., & Zhang, J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01749 · Cited by 176 · see citing works

The ras superfamily of small GTP-binding proteins

Downward, J. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90300-z · Cited by 175 · see citing works

Drug discovery for a new generation of covalent drugs

Kalgutkar, A. S. S., & Dalvie, D. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.688744 · Cited by 169 · see citing works

Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms

Lu, S., Shen, Q., & Zhang, J. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00570 · Cited by 166 · see citing works

The structural basis for the transition from Ras-GTP to Ras-GDP

Hall, B. E., Bar‐Sagi, D., & Nassar, N. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192453199 · Cited by 164 · see citing works

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials

Peeters, M., Kafatos, G., Taylor, A., Gastanaga, V. M., Oliner, K. S., Hechmati, G., Terwey, J.-H., & van Krieken, J. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.017 · Cited by 163 · see citing works

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 161 · see citing works

Molecular switch in signal transduction: Reaction paths of the conformational changes in ras p21

Ma, J., & Karplus, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.11905 · Cited by 156 · see citing works

Turning a protein kinase on or off from a single allosteric site via disulfide trapping

Sadowsky, J., Burlingame, M. A., Wolan, D. W., McClendon, C. L., Jacobson, M. P., & Wells, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102376108 · Cited by 155 · see citing works

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural &amp; Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153 · see citing works

Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function

Hocker, H. J., Cho, K.-J., Chen, C.-Y. K., Rambahal, N., Sagineedu, S. R., Shaari, K., Stanslas, J., Hancock, J. F., & Gorfe, A. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300016110 · Cited by 144 · see citing works

Reactive Metabolites: Current and Emerging Risk and Hazard Assessments

Thompson, R. A., Isin, E. M., Ogese, M. O., Mettetal, J. T., & Williams, D. P. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00410 · Cited by 141 · see citing works

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136 · see citing works

Inhibition of ras prenylation: A novel approach to cancer chemotherapy

Sebti, S. M., & Hamilton, A. D. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00014-4 · Cited by 134 · see citing works

A Structure-Guided Approach to Creating Covalent FGFR Inhibitors

Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 133 · see citing works

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Quevedo, C. E., Cruz-Migoni, A., Béry, N., Miller, A., Tanaka, T. U., Petch, D., Bataille, C. J. R., Lee, L. Y. W., Fallon, P. S., Tulmin, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05707-2 · Cited by 132 · see citing works

Sulindac sulfide inhibits Ras signaling

Herrmann, C., Block, C., Geisen, C., Haas, K., Weber, C. K., Winde, G., Möröy, T., & Müller, O. (1998) · Oncogene · doi:10.1038/sj.onc.1202085 · Cited by 129 · see citing works

Cancer: The Ras renaissance

Ledford, H. K. (2015) · Nature · doi:10.1038/520278a · Cited by 126 · see citing works

Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex

Taveras, A. G., Remiszewski, S., Doll, R. J., Cesarz, D., Huang, E. C., Kirschmeier, P. T., Pramanik, B. N., Snow, M. E., Wang, Y.-S., del Rosario, J., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00202-7 · Cited by 123 · see citing works

Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity

Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00382 · Cited by 120 · see citing works

Discovery of hidden allosteric sites as novel targets for allosteric drug design

Lu, S., Ji, M., Ni, D., & Zhang, J. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.001 · Cited by 118 · see citing works

Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery

Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116 · see citing works

Peptidomimetic inhibitors of APC–Asef interaction block colorectal cancer migration

Jiang, H., Deng, R., Yang, X., Shang, J., Lu, S., Zhao, Y., Song, K., Liu, X., Zhang, Q., Chen, Y., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2442 · Cited by 100 · see citing works

Covalent targeting of acquired cysteines in cancer

Visscher, M., Arkin, M. R., & Dansen, T. B. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.11.004 · Cited by 95 · see citing works

Interaction of Ras with phosphoinositide 3-kinase γ

Rubio, I., Rodriguez‐Viciana, P., Downward, J., & Wetzker, R. (1997) · Biochemical Journal · doi:10.1042/bj3260891 · Cited by 90 · see citing works

Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes

Shen, Q., Cheng, F., Song, H., Lü, W., Zhao, J., An, X., Liu, M., Chen, G., Zhao, Z., & Zhang, J. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.09.020 · Cited by 88 · see citing works

Ras and the Plasma Membrane: A Complicated RelationshipPreprint

Zhou, Y., Prakash, P., Gorfe, A. A., & Hancock, J. F. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031831 · Cited by 87 · see citing works

A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification

Nolte, W. M., Fortin, J.-P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1581 · Cited by 86 · see citing works

GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site

Lu, S., Banerjee, A., Jang, H., Zhang, J., Gaponenko, V., & Nussinov, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664755 · Cited by 86 · see citing works

Crystal structures of the state 1 conformations of the GTP‐bound H‐Ras protein and its oncogenic G12V and Q61L mutants

Muraoka, S., Shima, F., Araki, M., Inoue, T., Yoshimoto, A., Ijiri, Y., Seki, N., Tamura, A., Kumasaka, T., Yamamoto, M., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.058 · Cited by 81 · see citing works

Raf-1 Cysteine-Rich Domain Increases the Affinity of K-Ras/Raf at the Membrane, Promoting MAPK Signaling

Li, S., Jang, H., Zhang, J., & Nussinov, R. (2018) · Structure · doi:10.1016/j.str.2018.01.011 · Cited by 79 · see citing works

Calmodulin and PI3K Signaling in KRAS Cancers

Nussinov, R., Wang, G., Tsai, C., Jang, H., Lu, S., Banerjee, A., Zhang, J., & Gaponenko, V. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.01.007 · Cited by 78 · see citing works

Designing Irreversible Inhibitors—Worth the Effort?

González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74 · see citing works

Inhibitors of Ras–SOS Interactions

Lu, S., Jang, H., Zhang, J., & Nussinov, R. (2016) · ChemMedChem · doi:10.1002/cmdc.201500481 · Cited by 72 · see citing works

Covalent Guanosine Mimetic Inhibitors of G12C KRAS

Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66 · see citing works

The Ras AntagonistS-Farnesylthiosalicylic Acid Induces Inhibition of MAPK Activation

Gana‐Weisz, M., Haklai, R., Marciano, D., Egozi, Y., Ben‐Baruch, G., & Kloog, Y. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7582 · Cited by 61 · see citing works

Recent advances in cancer drug discovery targeting RAS

Wilson, C., & Tolias, P. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.002 · Cited by 59 · see citing works

Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange

Nnadi, C. I., Jenkins, M. L., Gentile, D. R., Bateman, L. A., Zaidman, D., Balius, T. E., Nomura, D. K., Burke, J. E., Shokat, K. M., & London, N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00399 · Cited by 58 · see citing works

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition

Najem, A., Krayem, M., Salès, F., Hussein, N., Badran, B. M., Robert, C., Awada, A. H., Journé, F., & Ghanem, G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.033 · Cited by 57 · see citing works

Slow conformational dynamics of the guanine nucleotide‐binding protein Ras complexed with the GTP analogue GTPγS

Spoerner, M., Nuehs, A., Herrmann, C., Steiner, G., & Kalbitzer, H. R. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05681.x · Cited by 56 · see citing works

Designed covalent allosteric modulators: an emerging paradigm in drug discovery

Lu, S., & Zhang, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.013 · Cited by 53 · see citing works

Comparison of the Conformations of KRAS Isoforms, K-Ras4A and K-Ras4B, Points to Similarities and Significant Differences

Chakrabarti, M., Jang, H., & Nussinov, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b11110 · Cited by 52 · see citing works

KRAS: Reasons for optimism in lung cancer

Lindsay, C. R., Jamal‐Hanjani, M., Forster, M. D., & Blackhall, F. H. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 52 · see citing works

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy

Spindler, K. G., Pallisgaard, N., Appelt, A. L., Andersen, R. F., Schou, J. V., Nielsen, D. L., Pfeiffer, P., Yilmaz, M., Johansen, J. S., Høgdall, E. V. S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.118 · Cited by 50 · see citing works

Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition

Chen, X., Makarewicz, J., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2013) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 46 · see citing works

Therapeutic modulation of k-ras signaling in colorectal cancer

Krens, L. L., Baas, J. M., Gelderblom, H. A. J., & Guchelaar, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.012 · Cited by 45 · see citing works

Efforts to Develop KRAS Inhibitors

Holderfield, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031864 · Cited by 43 · see citing works

Design, Synthesis and Biological Evaluation of Sugar‐Derived Ras Inhibitors

Peri, F., Airoldi, C., Colombo, S., Martegani, E., van Neuren, A. S., Stein, M., Marinzi, C., & Nicotra, F. (2005) · ChemBioChem · doi:10.1002/cbic.200400420 · Cited by 41 · see citing works

Dissecting allosteric effects of activator–coactivator complexes using a covalent small molecule ligand

Wang, N., Lodge, J. M., Fierke, C. A., & Mapp, A. K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406033111 · Cited by 36 · see citing works

Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity

Rao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.013 · Cited by 34 · see citing works

K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?

Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 30 · see citing works

Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation

Ni, D., Song, K., Zhang, J., & Lu, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112249 · Cited by 30 · see citing works

Simple One-Pot Synthesis of Disulfide Fragments for Use in Disulfide-Exchange Screening

Burlingame, M. A., Tom, C. T. M. B., & Renslo, A. R. (2011) · ACS Combinatorial Science · doi:10.1021/co200038g · Cited by 28 · see citing works

Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin

Ni, D., Liu, D., Zhang, J., & Lu, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010151 · Cited by 26 · see citing works

Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs

Quah, S. Y., Tan, M. S., Teh, Y. H., & Stanslas, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.010 · Cited by 25 · see citing works

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor

Wijeratne, A. B., Xiao, J., Reutter, C. T., Furness, K., Leon, R., Zia‐Ebrahimi, M., Cavitt, R. N., Strelow, J. M., Horn, R. D. V., Peng, S.-B., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00110 · Cited by 24 · see citing works

Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status

Thomsen, M., Guren, M. G., Skovlund, E., Glimelius, B. L. G., Hjermstad, M. J., Johansen, J. S., Kure, E. H., Sørbye, H., Pfeiffer, P., Christoffersen, T., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.026 · Cited by 21 · see citing works

Ras activation of phosphatidylinositol 3-kinase and akt

Rodriguez‐Viciana, P., & Downward, J. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)33042-2 · Cited by 17 · see citing works

The potential of targeting Ras proteins in lung cancer

McCormick, F. P. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.1000304 · Cited by 17 · see citing works

New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics

Esposito, D., Stephen, A. G., Turbyville, T. J., & Holderfield, M. T. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.006 · Cited by 16 · see citing works

Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective

Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608270 · Cited by 15 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 192 · see citing works

RAS: Striking at the Core of the Oncogenic Circuitry

Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174 · see citing works

Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy

Ni, D., Wei, J., He, X., Rehman, A. U., Li, X., Qiu, Y., Pu, J., Lu, S., & Zhang, J. (2020) · Chemical Science · doi:10.1039/d0sc05131d · Cited by 137 · see citing works

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Shi, C., Wang, Y., Wu, M., Chen, Y., Liu, F., Shen, Z., Wang, Y., Xie, S., Shen, Y., Sang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34346-x · Cited by 99 · see citing works

Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery

Lu, S., Qiu, Y., Ni, D., He, X., Pu, J., & Zhang, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.10.006 · Cited by 94 · see citing works

Mechanism of allosteric activation of SIRT6 revealed by the action of rationally designed activators

Lu, S., Chen, Y.-Y., Wei, J., Zhao, M., Ni, D., He, X., & Zhang, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.010 · Cited by 93 · see citing works

Unraveling allosteric landscapes of allosterome with ASD

Liu, X., Lu, S., Song, K., Shen, Q., Ni, D., Li, Q., He, X., Zhang, H., Wang, Q., Chen, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz958 · Cited by 73 · see citing works

Along the allostery stream: Recent advances in computational methods for allosteric drug discovery

Ni, D., Chai, Z., Wang, Y., Li, M., Yu, Z., Liu, Y., Lu, S., & Zhang, J. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1585 · Cited by 67 · see citing works

Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer

Cheng, J., Li, Y., Wang, X., Dong, G., & Sheng, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00929 · Cited by 67 · see citing works

Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras

Vatansever, S., Erman, B., & Gumus, Z. H. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.003 · Cited by 67 · see citing works

Ferroptosis: Promising approach for cancer and cancer immunotherapy

Zheng, S., & Guan, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216152 · Cited by 66 · see citing works

Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins

Wang, Y., Ji, D., Lei, C., Chen, Y., Qiu, Y., Li, X., Li, M., Ni, D., Pu, J., Zhang, J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.044 · Cited by 64 · see citing works

Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles

Yu, Z., He, X., Wang, R., Xu, X., Zhang, Z., Ding, K., Zhang, Z., Tan, Y., & Li, Z. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05899 · Cited by 63 · see citing works

The Ins and Outs of RAS Effector Complexes

Kiel, C., Matallanas, D., & Kölch, W. (2021) · Biomolecules · doi:10.3390/biom11020236 · Cited by 57 · see citing works

Drug design targeting active posttranslational modification protein isoforms

Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 56 · see citing works

Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication

Qiu, Y., Yin, X., Li, X., Wang, Y., Fu, Q., Huang, R., & Lu, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050747 · Cited by 54 · see citing works

40 Years of RAS—A Historic Overview

Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 53 · see citing works

AlloReverse: multiscale understanding among hierarchical allosteric regulations

Zha, J., Li, Q., Liu, X., Weidong, L., Wang, T., Wei, J., Zhang, Z., Lu, X., Wu, J., Ni, D., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad279 · Cited by 47 · see citing works

Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery

Fan, J., Liu, Y., Kong, R., Ni, D., Yu, Z., Lu, S., & Zhang, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01695 · Cited by 41 · see citing works

In-silico design of peptide inhibitors of K-Ras target in cancer disease

Ghufran, M., Rehman, A. U., Shah, M., Ayaz, M., Ng, H. L., & Wadood, A. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704880 · Cited by 42 · see citing works

Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B

Li, X., Dai, J., Ni, D., He, X., Zhang, H., Zhang, J., Fu, Q., Liu, Y., & Lu, S. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.020 · Cited by 38 · see citing works

Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain

Zhu, C., Lan, X., Wei, Z., Yu, J., & Zhang, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.020 · Cited by 37 · see citing works

Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators

Qiu, Y., Wang, Y., Chai, Z., Ni, D., Li, X., Pu, J., Chen, J., Zhang, J., Lu, S., Lv, C., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.014 · Cited by 37 · see citing works

SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer

Liu, M., Qin, Y., Hu, Q., Liu, W., Ji, S., Xu, W., Fan, G., Zeng, Y., Zhang, Z., Xu, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.023 · Cited by 36 · see citing works

Markov State Models and Molecular Dynamics Simulations Reveal the Conformational Transition of the Intrinsically Disordered Hypervariable Region of K-Ras4B to the Ordered Conformation

Zhang, H., Ni, D., Fan, J., Li, M.-Y., Zhang, J., Chen, H., Nussinov, R., & Lu, S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00591 · Cited by 36 · see citing works

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Wu, D., Sun, Q., Tang, H., Xiao, H., Luo, J., Ouyang, L., & Sun, Q. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101176 · Cited by 30 · see citing works

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 29 · see citing works

Computer-Aided Drug Design Boosts RAS Inhibitor Discovery

Wang, G., Bai, Y., Cui, J., Zong, Z., Gao, Y., & Zheng, Z. (2022) · Molecules · doi:10.3390/molecules27175710 · Cited by 27 · see citing works

Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors

Zhou, X., Ji, Y., & Zhou, J. (2023) · Molecules · doi:10.3390/molecules28083615 · Cited by 27 · see citing works

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 25 · see citing works

The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients

Liu, Y., Li, H., Zhu, J., Zhang, Y., Liu, X., Li, R., Zhang, Q., & Cheng, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s282617 · Cited by 24 · see citing works

KRAS G12C fragment screening renders new binding pockets

Mathieu, M., Steier, V., Fassy, F., Delorme, C., Papin, D., Genêt, B., Duffieux, F., Bertrand, T., Delarbre, L., Le-Borgne, H., et al. (2021) · Small GTPases · doi:10.1080/21541248.2021.1979360 · Cited by 24 · see citing works

CRISPR and KRAS: a match yet to be made

Bender, G., Yamaci, R. F., & Taneri, B. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00772-0 · Cited by 24 · see citing works

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C

Zhuang, H., Fan, J., Li, M., Zhang, H., Yang, X., Lin, L., Lu, S., Wang, Q., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915512 · Cited by 23 · see citing works

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis

Chen, Q., Lin, W., Zhou, X.-X., Cao, Z., Feng, X., Gao, Y., & He, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107060 · Cited by 21 · see citing works

How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study

Li, X., Ye, M., Wang, Y., Qiu, M., Fu, T., Zhang, J., Zhou, B., & Lu, S. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp03171b · Cited by 21 · see citing works

Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors

Li, B., Rong, D., & Wang, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011163410 · Cited by 20 · see citing works

Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R

Qi, W.-L., Li, H.-Y., Wang, Y., Xu, L., Deng, J.-T., Zhang, X., Wang, Y.-X., & Meng, L.-H. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01015-0 · Cited by 19 · see citing works

Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives

Tisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 18 · see citing works

Microsecond molecular dynamics simulations reveal the allosteric regulatory mechanism of p53 R249S mutation in p53-associated liver cancer

Liu, X., Tian, W., Cheng, J., Li, D., Liu, T., & Zhang, L. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107194 · Cited by 17 · see citing works

Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma

Wang, C.-X., Wang, T., Zhang, K.-D., Li, M., Shen, Q., Lu, S., & Zhang, J. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00897-4 · Cited by 16 · see citing works

Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain

Li, X.-Y., Qi, Z.-X., Ni, D., Lu, S.-Y., Chen, L., & Chen, X. (2021) · Molecules · doi:10.3390/molecules26185647 · Cited by 16 · see citing works

Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect

He, X., Du, K., Wang, Y., Fan, J., Li, M., Ni, D., Lu, S., Bian, X., & Liu, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.860962 · Cited by 13 · see citing works

The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins

Mou, M., Yang, W., Huang, G., Yang, X., Zhang, X. L., Kandegama, W., Ashby, C. R., Hao, G., & Gao, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.70001 · Cited by 13 · see citing works

Mechanistic Elucidation of Activation/Deactivation Signal Transduction within Neurotensin Receptor 1 Triggered by ‘Driver Chemical Groups’ of Modulators: A Comparative Molecular Dynamics Simulation

Lu, X., Shi, X., Fan, J., Li, M., Zhang, Y., Lu, S., Xu, G., & Chen, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15072000 · Cited by 8 · see citing works

The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells

Tisi, R., Spinelli, M., Palmioli, A., Airoldi, C., Cazzaniga, P., Besozzi, D., Nobile, M. S., Mazzoleni, E., Arnhold, S., GIOIA, L. D., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.625979 · Cited by 8 · see citing works

Direct KRAS inhibition: progress, challenges, and a glimpse into the future

Grapsa, D., & Syrigos, K. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760093 · Cited by 8 · see citing works

The ubiquitin code of RAS proteins: Decoding its role in cancer progression

Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 7 · see citing works

Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer

Yang, W., Gong, D.-H., Wu, H., Gao, Y., & Hao, G. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103705 · Cited by 7 · see citing works

An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review

Sabt, A., Tawfik, H. O., Khaleel, E. F., Badi, R. M., Ibrahim, H. A. A., Elkaeed, E. B., & Eldehna, W. M. (2024) · Molecular Diversity · doi:10.1007/s11030-023-10777-6 · Cited by 7 · see citing works

131I-C19 Iodide Radioisotope and Synthetic I-C19 Compounds as K-Ras4B–PDE6δ Inhibitors: A Novel Approach against Colorectal Cancer—Biological Characterization, Biokinetics and Dosimetry

Cruz-Nova, P., Ocampo‐García, B., Carrión-Estrada, D. A., Briseño-Díaz, P., Ferro‐Flores, G., Jiménez‐Mancilla, N., Correa‐Basurto, J., Bello, M., Vega, L., Thompson-Bonilla, M. D. R., et al. (2022) · Molecules · doi:10.3390/molecules27175446 · Cited by 6 · see citing works

Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry

Alawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., Moore, J., Maddern, G., Roder, D., Smith, A., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00856-9 · Cited by 5 · see citing works

RAS: Circuitry and therapeutic targeting

Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 5 · see citing works

Exploration of the selective binding mechanism of GSK3β via molecular modeling and molecular dynamics simulation studies

Mou, L., Ma, Z., Meng, X., Li, W., Liang, S., & Chen, X. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02514-7 · Cited by 5 · see citing works

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors

Kato, S., Porter, R., Okamura, R., Lee, S., Zelichov, O., Tarcic, G., Vidne, M., & Kurzrock, R. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.055 · Cited by 5 · see citing works

Breaking the PAM Restriction: A Universal Double Stranded DNA Detection Method Based on the Sticky End-Mediated CRISPR/Cas12a Coupled RPA and Its Application to KRAS G12C Single Base Mutations

He, X., Deng, L., Zhou, S., Gu, T., Li, X., Zhu, S., Luo, X., Huo, D., & Hou, C. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05908 · Cited by 4 · see citing works

Computational investigation of a ternary model of SnoN-SMAD3-SMAD4 complex

Ji, M., Ding, Y., Li, X., Mao, N., & Chen, J. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107159 · Cited by 4 · see citing works

The Role of the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Cancer

Lotfaliansaremi, S., Sabio, M. L., Comwell, S., & Tolias, P. P. (2020) · Medical Research Archives · doi:10.18103/mra.v8i4.2086 · Cited by 3 · see citing works

Protein–Protein Interactions in Cancer

Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_2 · Cited by 3 · see citing works

Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer

Briseño-Díaz, P., Michael Schnoor, A., Bello, M., Correa‐Basurto, J., Rojo‐Domínguez, A., Arregui, L., Vega, L., Núñez-González, E., Palau-Hernández, L. A., Parra-Torres, C. G., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202302019 · Cited by 3 · see citing works

Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer

Guo, Y., Jin, Y., Gao, J., Wang, D., Wang, Y., Shan, L., Yang, M., Li, X., & Ma, K. (2024) · Pharmaceuticals · doi:10.3390/ph17121696 · Cited by 2 · see citing works

Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future

Veiga, A., Queipo, F. J., Bou, G., Cepeda‐Emiliani, A., & Concha, Á. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00049-1 · Cited by 2 · see citing works

Anticancer drugs acting on signaling pathways, part 2: Inhibitors of serine-threonine kinases and miscellaneous signaling pathways

Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00011-x · Cited by 1 · see citing works

Predicting GPR40 Agonists with A Deep Learning‐Based Ensemble Model

Yang, J., Jiang, C., Chen, J., Qin, L., & Cheng, G. (2023) · ChemistryOpen · doi:10.1002/open.202300051 · Cited by 1 · see citing works

FAM65A promotes the progression and growth of lung squamous cell carcinoma in vivo and vitro

Chen, F., Ren, P., Xu, R., Zhang, J., Liang, C., & Qiang, G. (2024) · BMC Cancer · doi:10.1186/s12885-024-12701-z · Cited by 1 · see citing works

Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment

Abdel‐Magid, A. F. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00428 · Cited by 1 · see citing works

After Decades, RAS Mutation has Finally Become a Therapeutic Target

Naim, N., Moukheiber, S., Jaber, K., & Kourié, H. R. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0015

A computational study to reveal selpercatinib resistance to RET kinase double mutant V804M/Y806C

Zheng, G., Li, M.-Y., Zhang, J., Liu, W., Jiang, L., Liang, W., Wang, J., Shi, H., Kang, Z., & Zhou, B. (2022) · Chemical Papers · doi:10.1007/s11696-022-02479-4

Therapeutic peptidomimetics for cancer treatment

Avendaño, C., & Menéndez, J. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00010-8

Pharmaceutical Research Based on the Structure of KRAS Protein—Research and Practice on Teaching Reform of Biochemistry Course

曹, 修. (2023) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2023.133039

Targeting KRAS G12C: progress made and promise ahead

Huiqi, H., Fang, S., & Song, J. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3013204

Research Advances in KRAS Mutation Cancer Treatment Strategies: From “Undruggable” Targets to Diversified Precision Therapies

朱, 含. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161317

BindingDB Entry 50010796: Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.

BindingDB (2021) · UC San Diego · doi:10.7270/q2rn3cfh

KRasG12C inhibitors in clinical trials: a short historical perspective

Goebel, L., Müller, M. P., Goody, R. S., & Rauh, D. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00096e · Cited by 127 · see citing works

Structure-based inhibitor design of mutant RAS proteins—a paradigm shift

Nyíri, K., Koppány, G., & Vértessy, B. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09914-6 · Cited by 27 · see citing works

Abstract C049: Identification of novel K-Ras G12C inhibitors using a DNA encoded library platform

Arora, S., Hupp, C. D., Talcott, S. A., Narayanan, U., Gikunju, D., Rechenberg, M. V., Monteiro, M. I., Giulinger, J. P., Denton, K. E., Clark, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-19-c049 · Cited by 5 · see citing works

Inhibition of RAS: proven and potential vulnerabilities

Zuberi, M., Khan, I., & O’Bryan, J. P. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190023 · Cited by 20 · see citing works

Abstract IA20: Unlocked groove—developing covalent inhibitors of KRASG12C

Lipford, J. R., Cee, V. J., Lanman, B. A., Saiki, A. Y., Rex, K. L., Volak, L. P., Shimanovich, R., & Hinkle, B. (2020) · Molecular Cancer Research · doi:10.1158/1557-3125.ras18-ia20